Share on StockTwits

Research analysts at TheStreet assumed coverage on shares of Physicians Realty Trust (NYSE:DOC) in a report released on Thursday. The firm set a “hold” rating on the stock.

A number of other firms have also recently commented on DOC. Analysts at Zacks downgraded shares of Physicians Realty Trust from a “neutral” rating to an “underperform” rating in a research note on Tuesday. They now have a $13.70 price target on the stock. Separately, analysts at Compass Point raised their price target on shares of Physicians Realty Trust from $16.00 to $16.50 in a research note on Thursday, August 14th. Finally, analysts at Oppenheimer raised their price target on shares of Physicians Realty Trust from $14.00 to $15.50 in a research note on Monday, August 11th. They now have an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $15.21.

Physicians Realty Trust (NYSE:DOC) traded down 0.27% during mid-day trading on Thursday, hitting $14.55. The stock had a trading volume of 41,230 shares. Physicians Realty Trust has a 52 week low of $11.00 and a 52 week high of $14.77. The stock’s 50-day moving average is $14.34 and its 200-day moving average is $13.68. The company’s market cap is $493.9 million.

Physicians Realty Trust (NYSE:DOC) last issued its quarterly earnings data on Wednesday, August 13th. The company reported $0.17 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.23 by $0.06. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $10.40 million. Analysts expect that Physicians Realty Trust will post $0.78 EPS for the current fiscal year.

Physicians Realty Trust is a real estate investment trust (NYSE:DOC).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.